Online Inquiry

Global Services. (Creative Biolabs Authorized)

Homologous Recombination Sequence Modeling & Evolution Prediction Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Current challenges in vector design include the inability to reliably predict homologous recombination (HR) events that may lead to replication-competent viruses, compromising safety and efficacy. Our Homologous Recombination Sequence Modeling & Evolution Prediction Services addresses this gap by integrating bioinformatic and molecular assessments of vector sequences to minimize HR risks. We provide in silico modeling of recombination hotspots, evolutionary trajectory simulations, and empirical validation of vector candidates. By predicting recombination-prone regions pre-synthesis, our service enables safer vector design, accelerates regulatory approval, and reduces costly wet-lab failures, offering confidence for gene therapy and vaccine development.

Introduction

Replication-competent vector homologous recombination denotes the restoration of viral self-replication capacity through genetic exchange between vector constructs and homologous templates, including helper plasmids, host chromosomal regions, or concurrent vector systems. Such events represent a principal safety concern in therapeutic gene delivery and vaccine platforms, given that rare recombinational rescue can yield propagating viruses capable of triggering genotoxicity, systemic dissemination, or immune dysregulation, hazards that conventional sequence comparison methods frequently fail to foresee.

Fig.1 Recombination-driven evolution of positive-sense RNA viruses. (OA Literature) Fig.1 Recombination in positive-sense RNA viruses.¹

Our Service

Our Homologous Recombination Sequence Modeling & Evolution Prediction Services integrate bioinformatic homology scanning, structural modeling, and evolutionary simulations to systematically identify and mitigate recombination risks in viral vectors. By predicting replication-competent variants pre-synthesis, we enable safer vector design, accelerate regulatory approval, and reduce costly failures, delivering confidence for gene therapy and vaccine development.

What We Can Offer

We offer a comprehensive suite of computational strategies to model homologous recombination risks, including homology mapping, hotspot scanning, structural and thermodynamic analysis, repeat characterization, microhomology prediction, and sequence deoptimization for safer vector design.

Featured services of homologous recombination sequence modeling & evolution prediction services at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Vector Sequences for Evaluation: We require plasmid sequences, viral backbones, or specific DNA/RNA sequence files submitted in standard formats.
Host or Helper Genome Context: We incorporate host cell genomic background or helper plasmid sequences to assess homology-driven recombination risks

Key Steps:

Workflow of homologous recombination sequence modeling & evolution prediction services at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Comprehensive Risk Assessment Report.
Optimized Vector Sequence.
Data Visualization Charts.

Key Advantages

Proactive Risk Prediction: We identify homologous recombination hotspots before vector synthesis, preventing replication-competent virus formation at the design stage rather than detecting failures late in development.
Integrated Bioinformatic & Molecular Workflow: We combine in silico modeling with optional empirical validation, bridging computational predictions and biological relevance for higher accuracy.
Cost & Time Efficiency: We minimize costly wet-lab failures and iterative redesign cycles, enabling clients to focus resources on lead candidates with validated safety profiles.

FAQ

Q1: What types of vectors can this service evaluate?

A1: We evaluate lentiviral, AAV, gamma-retroviral, non-viral plasmids, and RNA-based vector systems, including those with split packaging or self-inactivating designs.

Q2: What is the turnaround time for a standard project?

A2: Typical turnaround ranges from 2 to 4 weeks, depending on vector complexity and whether optional wet-lab validation is requested.

Q3: What formats do you accept for starting materials?

A3: We accept FASTA, GenBank, or plain-text sequence files, along with host genome references or helper plasmid sequences when available.

Why Choose Us?

Choose us for unparalleled expertise in predicting and mitigating homologous recombination risks. We combine advanced bioinformatic modeling, evolutionary simulations, and optional wet-lab validation to deliver safer vector designs. Our proactive approach accelerates regulatory approval, reduces costly failures, and provides documented confidence for gene therapy and vaccine development.

Customer Reviews

"Our gamma-retroviral vector carried extensive repetitive elements that raised safety concerns. The homology scanning and microhomology prediction modules pinpointed exactly which regions were prone to recombination. We modified the vector accordingly, and subsequent empirical testing confirmed zero recombination events even under selective pressure." Dr. P* S*.

"We used the evolution prediction arm to simulate how our split-vector system might recombine with endogenous retroviral sequences in target cells. The service not only identified the recombination-prone regions but also provided an optimized sequence with redesigned codon usage. The final vector showed unprecedented stability in our in vivo models." Dr. A* W*.

How to contact us?

We invite you to discuss your vector safety challenges with our expert team. Contact us to request a customized project plan, receive a confidential quote, or schedule a technical consultation. Let us help you minimize recombination risks and accelerate your gene therapy or vaccine development program with confidence.

Reference

Wang, Haiwei et al. "Recombination in Positive-Strand RNA Viruses." Frontiers in microbiology vol. 13 870759. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fmicb.2022.870759.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.